Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Jefferies Group increased their FY2017 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday. Jefferies Group analyst M. Yee now forecasts that the biopharmaceutical company will post earnings per share of ($7.43) for the year, up from their prior estimate of ($7.45). Jefferies Group currently has a “Buy” rating and a $85.00 price target on the stock. Jefferies Group also issued estimates for Esperion Therapeutics’ Q4 2017 earnings at ($1.86) EPS and FY2018 earnings at ($8.54) EPS.

Several other analysts have also commented on ESPR. BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Needham & Company LLC raised their price target on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research report on Tuesday, August 8th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and set a $70.00 price target (up previously from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $58.92.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Set Expectations for Esperion Therapeutics, Inc.’s FY2017 Earnings (ESPR)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/09/equities-analysts-set-expectations-for-esperion-therapeutics-inc-s-fy2017-earnings-espr.html.

Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at $47.60 on Thursday. Esperion Therapeutics has a 52-week low of $9.51 and a 52-week high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the business posted ($0.77) EPS.

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Tower Research Capital LLC TRC boosted its position in Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 4,856 shares during the last quarter. Aperio Group LLC acquired a new position in Esperion Therapeutics during the second quarter worth about $249,000. American International Group Inc. boosted its position in Esperion Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 584 shares during the last quarter. SG Americas Securities LLC boosted its position in Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 2,991 shares during the last quarter. Finally, Voya Investment Management LLC boosted its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 806 shares during the last quarter. Hedge funds and other institutional investors own 90.05% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.